Critical reviews in oncology/hematology最新文献

{"title":"Cardio-oncology concerns in radiotherapy: Heart and cardiac substructure toxicities from modern delivery techniques","authors":"Ioana-Claudia Costin ,&nbsp;Corina Cinezan ,&nbsp;Loredana G. Marcu","doi":"10.1016/j.critrevonc.2024.104538","DOIUrl":"10.1016/j.critrevonc.2024.104538","url":null,"abstract":"<div><div>Cardio-oncology is lately gaining more attention due to radiation-induced cardiac events reported by a very large number of studies. In view of this, the current overview of the literature aimed to encompass all studies from the past 15 years to assess changes in cardiac dose due to treatment evolution, as well as the changes in treatment planning customs to incorporate not only the heart as a whole but also cardiac substructures. Modern treatment techniques, particularly proton therapy, offers superior cardiac sparing compared to more established radiotherapy, for all evaluated tumor sites. Intensity modulation, particularly coupled with respiratory gating shows significant improvement in dose-volume parameters pertaining to the heart. While past studies considered mean heart dose as the only reference for cardiac toxicities, recommendations for the other cardiac substructures to be dosimetrically assessed during planning are becoming more common.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104538"},"PeriodicalIF":5.5,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymph node metastasis in cancer: Clearing the clouds to see the dawn","authors":"Zi-Zhan Li ,&nbsp;Kan Zhou ,&nbsp;Qiuji Wu ,&nbsp;Bing Liu ,&nbsp;Lin-Lin Bu","doi":"10.1016/j.critrevonc.2024.104536","DOIUrl":"10.1016/j.critrevonc.2024.104536","url":null,"abstract":"<div><div>Lymph node metastasis (LNM) is often regarded as an indicator of poor prognosis in various cancers. Despite over three centuries of exploration since its discovery, the molecular mechanisms underlying LNM remain inconclusive. This review summarizes the molecular mechanisms of LNM, using the \"PUMP+\" principle for clarification. Pathological examination remains the gold standard for LNM diagnosis, yet there is a need to explore early diagnostic strategies that can effectively improve patient outcomes. With the advent of immunotherapy, discussions on the fate of lymph nodes (LN) have emerged, emphasizing the importance of preserving LN integrity prior to immunotherapy. This, in turn, poses higher demands for diagnostic accuracy and precision treatment of LNM. This review comprehensively discusses the molecular mechanisms, diagnostic methods, and treatment strategies for cancer lymph node metastasis, along with current bottlenecks and future directions in this field.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104536"},"PeriodicalIF":5.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scientific Communication and oncology – \"The bridge between knowledge and patients\"","authors":"Antonio Galvano ,&nbsp;Andrea Gottardo ,&nbsp;Valerio Gristina ,&nbsp;Daniele Fanale ,&nbsp;Lidia Rita Corsini ,&nbsp;Carlo Pavone ,&nbsp;Tancredi Didier Bazan Russo ,&nbsp;Emilia Di Giovanni ,&nbsp;Giuliana Iannì ,&nbsp;Ugo Randazzo ,&nbsp;Federica Iacono ,&nbsp;Alessandro Perez ,&nbsp;Chiara Brando ,&nbsp;Marco Bono ,&nbsp;Viviana Bazan ,&nbsp;Lorena Incorvaia ,&nbsp;Giuseppe Badalamenti ,&nbsp;Saverio Cinieri ,&nbsp;Mauro Boldrini ,&nbsp;Rossana Berardi ,&nbsp;Antonio Russo","doi":"10.1016/j.critrevonc.2024.104531","DOIUrl":"10.1016/j.critrevonc.2024.104531","url":null,"abstract":"<div><div>The communication of scientific knowledge to patients and society as a whole has never been more central than in modern times. Thanks to the recent pandemic, it has become evident how Scientific Communication (SC) has evolved over time, increasingly diverging from common language. However, it is also clear that it must be properly used by healthcare professionals to avoid comprehension issues that could be severe for the audience. Presently, science and technology are at the heart of progress and innovation; therefore, the proper dissemination of accurate yet accessible information to the population is vital to ensure that no one is left behind and to promote cohesive social advancement. This review aims to analyze the notions of SC and Scientific Method (SM), examining the relationships between them and providing suggestions on how to integrate them properly in both a broader context and the specific field of communication with oncology patients.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104531"},"PeriodicalIF":5.5,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early cancer detection using deep learning and medical imaging: A survey","authors":"Istiak Ahmad ,&nbsp;Fahad Alqurashi","doi":"10.1016/j.critrevonc.2024.104528","DOIUrl":"10.1016/j.critrevonc.2024.104528","url":null,"abstract":"<div><div>Cancer, characterized by the uncontrolled division of abnormal cells that harm body tissues, necessitates early detection for effective treatment. Medical imaging is crucial for identifying various cancers, yet its manual interpretation by radiologists is often subjective, labour-intensive, and time-consuming. Consequently, there is a critical need for an automated decision-making process to enhance cancer detection and diagnosis. Previously, a lot of work was done on surveys of different cancer detection methods, and most of them were focused on specific cancers and limited techniques. This study presents a comprehensive survey of cancer detection methods. It entails a review of 99 research articles collected from the Web of Science, IEEE, and Scopus databases, published between 2020 and 2024. The scope of the study encompasses 12 types of cancer, including breast, cervical, ovarian, prostate, esophageal, liver, pancreatic, colon, lung, oral, brain, and skin cancers. This study discusses different cancer detection techniques, including medical imaging data, image preprocessing, segmentation, feature extraction, deep learning and transfer learning methods, and evaluation metrics. Eventually, we summarised the datasets and techniques with research challenges and limitations. Finally, we provide future directions for enhancing cancer detection techniques.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104528"},"PeriodicalIF":5.5,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting epigenetic mechanisms of resistance to chemotherapy in gliomas","authors":"Panagiotis Skouras ,&nbsp;Mariam Markouli ,&nbsp;Ioanna Papadatou ,&nbsp;Christina Piperi","doi":"10.1016/j.critrevonc.2024.104532","DOIUrl":"10.1016/j.critrevonc.2024.104532","url":null,"abstract":"<div><div>Glioma, an aggressive type of brain tumors of glial origin is highly heterogeneous, posing significant treatment challenges due to its intrinsic resistance to conventional therapeutic schemes. It is characterized by an interplay between epigenetic and genetic alterations in key signaling pathways which further endorse their resistance potential. Aberrant DNA methylation patterns, histone modifications and non-coding RNAs may alter the expression of genes associated with drug response and cell survival, induce gene silencing or deregulate key pathways contributing to glioma resistance. There is evidence that epigenetic plasticity enables glioma cells to adapt dynamically to therapeutic schemes and allow the formation of drug-resistant subpopulations. Furthermore, the tumor microenvironment adds an extra input on epigenetic regulation, increasing the complexity of resistance mechanisms. Herein, we discuss epigenetic changes conferring to drug resistance mechanisms in gliomas in order to delineate novel therapeutic targets and potential approaches that will enable personalized treatment.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104532"},"PeriodicalIF":5.5,"publicationDate":"2024-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142445766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis","authors":"Silvia Belloni ,&nbsp;Paola Tiberio ,&nbsp;Rita De Sanctis ,&nbsp;Arianna Magon ,&nbsp;Armando Santoro ,&nbsp;Alberto Zambelli ,&nbsp;Rosario Caruso ,&nbsp;Cristina Arrigoni","doi":"10.1016/j.critrevonc.2024.104527","DOIUrl":"10.1016/j.critrevonc.2024.104527","url":null,"abstract":"<div><div>Antibody-drug conjugates (ADCs) are revolutionizing metastatic breast cancer treatment, resulting in a better prognosis and a higher safety profile than chemotherapy. Nevertheless, treatment-related adverse events (TRAE) have been extensively documented. We searched five databases for articles published up to December 2023 and conducted a meta-analysis on 23 clinical trials to estimate TRAE prevalence related to currently approved ADCs.</div><div>The prevalence of the most common TRAEs ranged from 12 % to 33 %, depending on the ADC type and study design. Gastrointestinal disorders were highly prevalent during Trastuzumab Deruxtecan, general disorders were extremely common during Trastuzumab Emtansine, and blood system disorders and gastrointestinal disorders were the most prevalent during Sacituzumab Govitecan.</div><div>This study provides an estimate of ADC-related TRAEs for each treatment based on study design. Despite each ADC having specific toxicities, gastrointestinal symptoms were highly prevalent in all treatments. This study lays the groundwork for developing personalized risk-stratified care pathways.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104527"},"PeriodicalIF":5.5,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142434020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between peripheral whole blood cell counts derived indexes and cancer prognosis: An umbrella review of meta-analyses of cohort studies","authors":"Ying-Ying Zhang ,&nbsp;Fang-Hua Liu ,&nbsp;Ya-Li Wang ,&nbsp;Jia-Xin Liu ,&nbsp;Lang Wu ,&nbsp;Ying Qin ,&nbsp;Wen-Rui Zheng ,&nbsp;Wei-Yi Xing ,&nbsp;Jin Xu ,&nbsp;Xing Chen ,&nbsp;He-Li Xu ,&nbsp;Qi Bao ,&nbsp;Jia-Yi Wang ,&nbsp;Ran Wang ,&nbsp;Xi-Yang Chen ,&nbsp;Yi-Fan Wei ,&nbsp;Bing-Jie Zou ,&nbsp;Jia-Cheng Liu ,&nbsp;Jia-Li Yin ,&nbsp;Ming-Qian Jia ,&nbsp;Qi-Jun Wu","doi":"10.1016/j.critrevonc.2024.104525","DOIUrl":"10.1016/j.critrevonc.2024.104525","url":null,"abstract":"<div><div>Meta-analyses have reported conflicting data on the whole blood cell count (WBCC) derived indexes (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyte ratio [PLR], and lymphocyte-to-monocyte ratio [LMR]) and cancer prognosis. However, the strength and quality of this evidence has not been quantified in aggregate. To grade the evidence from published meta-analyses of cohort studies that investigated the associations between NLR, PLR, and LMR and cancer prognosis. A total of 694 associations from 224 articles were included. And 219 (97.8%) articles rated as moderate-to-high quality according to AMSTAR. There were four associations supported by convincing evidence. Meanwhile, 165 and 164 associations were supported by highly suggestive and suggestive evidence, respectively. In this umbrella review, we summarized the existing evidence on the WBCC-derived indexes and cancer prognosis. Due to the direction of effect sizes is not completely consistent between studies, further research is needed to assess causality and provide firm evidence.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104525"},"PeriodicalIF":5.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How safe and effective is irradiating radiation-induced meningiomas? Single-center experience in primary and salvage Gamma-Knife Radiosurgery, systematic review, and metanalysis of current evidence on the topic","authors":"Filippo Gagliardi ,&nbsp;Pierfrancesco De Domenico ,&nbsp;Silvia Snider,&nbsp;Riccardo Calcagnile,&nbsp;Francesca Roncelli,&nbsp;Lina Raffaella Barzaghi,&nbsp;Pietro Mortini","doi":"10.1016/j.critrevonc.2024.104526","DOIUrl":"10.1016/j.critrevonc.2024.104526","url":null,"abstract":"<div><div>This is a single-center experience and metanalysis of the safety and efficacy measures of Gamma-knife stereotactic radiosurgery (SRS-GK) for radiation-induced meningiomas (RIMs). This study comprised a single-center analysis of SRS-GK for RIMs at IRCCS San Raffaele Hospital, Milan, Italy, and a systematic literature review and meta-analysis to address the actuarial local control (LC), distant control (DC), progression-free survival (PFS), and toxicity. The original series comprised 13 patients harboring 30 RIMs. Partial response was observed in 26 %, stability in 52 %, and progression in 22 %. The 5-year LC and DC rates were 71 % and 67 %. One patient developed radionecrosis, and an additional 2 presented edema. Metanalysis comprised 4 papers and data from the original series, comprising 146 patients and 308 RIMs. The 5-year LC was 84 %, the DC 67 %, and radionecrosis in 1.4 %. SRS-GK has an efficacy profile falling between that observed for radiologically suspected sporadic meningiomas and confirmed higher-grade lesions.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104526"},"PeriodicalIF":5.5,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in randomized controlled trials of therapeutic interventions for multiple myeloma: A systematic review","authors":"Maria Mainou ,&nbsp;Kalliopi Tsapa ,&nbsp;Theodoros Michailidis ,&nbsp;Konstantinos Malandris ,&nbsp;Thomas Karagiannis ,&nbsp;Ioannis Avgerinos ,&nbsp;Aris Liakos ,&nbsp;Maria Papaioannou ,&nbsp;Evangelos Terpos ,&nbsp;Vinay Prasad ,&nbsp;Apostolos Tsapas","doi":"10.1016/j.critrevonc.2024.104529","DOIUrl":"10.1016/j.critrevonc.2024.104529","url":null,"abstract":"<div><h3>Purpose</h3><div>Many clinical trials of therapeutic interventions for multiple myeloma do not use patient important outcomes and rely on the use of surrogate endpoints. The aim of this systematic review was to depict the landscape of randomized controlled trials in myeloma research and compile the endpoints utilized.</div></div><div><h3>Methods</h3><div>We searched Embase, PubMed, and the Cochrane Library for randomized controlled trials in myeloma published in English up to October 2023. We included trials exploring efficacy of therapeutic modalities for myeloma itself or supportive care interventions.</div></div><div><h3>Results</h3><div>A total of 2181 records, reporting data from 624 trials (448 comparing anti-myeloma treatments and 176 comparing supportive interventions) were deemed eligible. The most common primary outcome reported was disease response, followed by progression free survival (PFS) and overall survival (OS). Across all trials, 119 (19.1 %) used OS as the primary endpoint, while 316 (50.6 %) listed it as a secondary endpoint. Quality of life was less commonly prioritized, featured as primary endpoint only in seven studies (1.1 %) and as secondary endpoint in 115 studies (18.4 %). Studies funded by the pharmaceutical industry were more likely (Odds Ratio [OR] 3.85, 95 % CI 2.41–6.35) to use PFS as primary outcome. Similarly, studies with authors that had conflicts of interest with the funding source were more likely (OR 4.57, 95 % CI 2.72–7.92) to use PFS as the primary outcome.</div></div><div><h3>Conclusion</h3><div>While randomized controlled trials for multiple myeloma predominantly rely on surrogate endpoints, particularly PFS, the importance of OS as an outcome should not be overlooked.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104529"},"PeriodicalIF":5.5,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials","authors":"Qi Wang ,&nbsp;Jianan Yu ,&nbsp;Xuedong Sun ,&nbsp;Jian Li ,&nbsp;Shasha Cao ,&nbsp;Yanjing Han ,&nbsp;Haochen Wang ,&nbsp;Zeran Yang ,&nbsp;Jianjun Li ,&nbsp;Caixia Hu ,&nbsp;Yonghong Zhang ,&nbsp;Long Jin","doi":"10.1016/j.critrevonc.2024.104522","DOIUrl":"10.1016/j.critrevonc.2024.104522","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Purpose&lt;/h3&gt;&lt;div&gt;For patients with advanced or unresectable hepatocellular carcinoma (HCC), safe and effective therapies are urgently needed to improve their long-term prognosis. Although the guidelines recommend first-line treatments such as sorafenib, lenvatinib, and atezolizumab in combination with bevacizumab (T+A) and second-line treatments such as regorafenib, the efficacy comparison between drugs is lacking, that is, a treatment is not recommended as the optimal or alternative choice for a specific patient population. Therefore, we will conduct a high-quality network meta-analysis based on Phase III randomized controlled trials (RCTs) to systematically evaluate and compare overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and serious adverse events (SAE) of different treatment protocols in the context of first-line and second-line therapies, which are critical for clinical decision making and prognostic improvement in advanced HCC patients.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The studies of interest were Phase III RCTs evaluating the efficacy or safety of first- or second-line therapies in patients with unresectable or advanced HCC. Literature published in English from the four databases of PubMed, Embase, Cochrane Library, and Web of Science was comprehensively searched from the inception to May 23, 2022. Outcomes of interest included OS, PFS, ORR, and SAE. A league table was developed to show the results of the comparison between different treatments. A histogram of cumulative probability was drawn to discuss the ranking probability of treatments based on different outcomes. The effectiveness and safety of various treatments were comprehensively considered and the two-dimensional diagram was plotted to guide clinical practice. The Gemtc package in R Studio was used for network meta-analysis in a Bayesian framework.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;The results showed that HAIC-FO was superior to T+A regimen, regardless of OS, PFS or ORR. TACE combined with lenvatinib performed better than T+A in PFS, and ORR. In addition to the T+A regimen, Sintilimab combined with IBI305 and camrelizumab combined with apatinib were also associated with longer OS, PFS, and ORR, and their SAE incidence was not higher than that of T+A, especially for camrelizumab combined with apatinib, its safety was better than that of T+A regimen. There were no new treatments or combinations that were more effective than regorafenib. It was important to note that for PFS, the efficacy of apatinib and cabozantinib was not statistically different from that of regorafenib, so these two treatments could be used as alternative treatment options in cases where regorafenib was not tolerated or treatment failed.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;We conducted a network meta-analysis to evaluate the efficacy and safety of multiple treatment modalities by integrating the results of direct and indirect comparisons. This study","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"204 ","pages":"Article 104522"},"PeriodicalIF":5.5,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}